Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin.A disulfide-linked oligomer of two alpha and two beta subunits makes up the receptor. The two insulin receptor isoforms, IR-A and IR-B, are present and expressed in various organs and tissues in varying amounts. The binding affinities of the two IR isoforms for insulin and the insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B, are comparable.
Controlling glucose homeostasis, regulating lipid, protein, and carbohydrate metabolism, and modifying levels of brain neurotransmitters are all important functions of the insulin receptor. Diabetes, cancer, and Alzheimer's disease are just a few of the illnesses that have been linked to insulin receptor dysfunction.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69526 | (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) | 299898-52-5 | (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is a potent, stable and specific full agonist of the human GIP receptor. |
|
V85919 | (Pro3) GIP, human TFA ((Pro3) Gastric Inhibitory Peptide, human TFA) | ||
|
V69511 | [D-Ala2]-GIP (human) | 444073-04-5 | [D-Ala2]-GIP (human) is a GIP receptor agonist. |
|
V77485 | [Pro3]-GIP (Mouse) | [Pro3]-GIP (Mouse) is a GIP receptor antagonist (IC50= 2.6 μM). | |
|
V119691 | [Pro3]-GIP (Rat) | [Pro3]-GIP (rat) is a selective partial agonist of the GIP receptor with a Ki value of 13 nM. | |
|
V69527 | [Tyr0] Gastric Inhibitory Peptide (23-42), human | 121765-67-1 | [Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak gastric acid secretion inhibitor and can also stimulate insulin secretion. |
|
V69523 | Acetyl Gastric Inhibitory Peptide (human) (Human N-acetyl GIP) | 299898-33-2 | Acetyl Gastric Inhibitory Peptide (human) is a fatty acid-derived analog of a glucose-dependent insulinogenic peptide with improved antihyperglycemic and insulinogenic properties. |
|
V77299 | Acetyl Gastric Inhibitory Peptide (human) (TFA) (Human N-acetyl GIP TFA) | Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid-derived analog of a glucose-dependent insulinogenic peptide with improved antihyperglycemic and insulinogenic properties. | |
|
V128118 | Acetyl Gastric Inhibitory Peptide (human) TFA | Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivative analog of a glucose-dependent insulinotropic peptide with enhanced hypoglycemic and insulin secretion-promoting properties. | |
|
V69519 | Aganirsen | 1146887-67-3 | Aganirsen is an antisense oligonucleotide (25 nucleotides) that can inhibit insulin receptor substrate 1 (IRS-1). |
|
V77856 | Aganirsen sodium | Aganirsen sodium is an antisense oligonucleotide (25 nucleotides) that can inhibit insulin receptor substrate 1 (IRS-1). | |
|
V128390 | Aganirsen sodium scrambled negative control | The Aganirsen sodium scrambled negative control is a negative control with the sequence of Aganirsen sodium scrambled. | |
|
V128418 | AGT-182 | AGT-182 is an anti-human insulin receptor antibody that can penetrate the blood-brain barrier and is conjugated with iduronic acid-2-sulfatase. | |
|
V128537 | ALK-IN-24 | 2093414-37-8 | ALK-IN-24 is an orally effective ALK inhibitor with an IC50 value of 1.7 nM. |
|
V69514 | AVJ16 | 2775241-92-2 | AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA-binding protein IGF2BP1 and can inhibit the migration of H1299 cells that highly express endogenous IGF2BP1. |
|
V129960 | BDM71230 | BDM71230 is an orally effective insulin-degrading enzyme (IDE) inducer with an EC50 value of 1.9 μM for human IDE. | |
|
V112389 | Centpiperalone | 22587-11-7 | Semperaprone is an effective oral hypoglycemic agent. |
|
V131785 | cis-NVP-ADW742 | 475489-15-7 | cis-NVP-ADW742 is the cis isomer of NVP-ADW742. |
|
V88057 | D-Galactose pentaacetate | 25878-60-8 | D-Galactose pentaacetate can inhibit leucine-induced insulin release. |
|
V69520 | DA-JC4 | 2315504-40-4 | DA-JC4 is a dual GLP-1/GIP receptor agonist (activator) that may be utilized to study neurological diseases and insulin signaling pathways. |